Xvivo Perfusion AB
STO:XVIVO

Watchlist Manager
Xvivo Perfusion AB Logo
Xvivo Perfusion AB
STO:XVIVO
Watchlist
Price: 184.4 SEK -0.7% Market Closed
Market Cap: 5.8B SEK

Profitability Summary

Xvivo Perfusion AB's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Xvivo Perfusion AB

Revenue
813.6m SEK
Cost of Revenue
-203m SEK
Gross Profit
610.5m SEK
Operating Expenses
-543.5m SEK
Operating Income
67m SEK
Other Expenses
-37.1m SEK
Net Income
29.9m SEK

Margins Comparison
Xvivo Perfusion AB Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
SE
Xvivo Perfusion AB
STO:XVIVO
5.8B SEK
75%
8%
4%
JP
Hoya Corp
TSE:7741
8.2T JPY
86%
30%
24%
CH
Alcon AG
SIX:ALC
31.8B CHF
54%
14%
10%
DK
Coloplast A/S
CSE:COLO B
126.6B DKK
68%
28%
13%
US
Align Technology Inc
NASDAQ:ALGN
11.4B USD
69%
16%
10%
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
46.5B CNY
68%
38%
36%
UK
ConvaTec Group PLC
LSE:CTEC
4.6B GBP
56%
15%
9%
CA
Bausch + Lomb Corp
NYSE:BLCO
5.9B USD
59%
2%
-6%
CH
Ypsomed Holding AG
SIX:YPSN
4.2B CHF
41%
28%
25%
JP
Asahi Intecc Co Ltd
TSE:7747
823.8B JPY
68%
25%
11%
US
Merit Medical Systems Inc
NASDAQ:MMSI
4.9B USD
48%
11%
8%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Xvivo Perfusion AB Competitors

Country Company Market Cap ROE ROA ROCE ROIC
SE
Xvivo Perfusion AB
STO:XVIVO
5.8B SEK
1%
1%
3%
2%
JP
Hoya Corp
TSE:7741
8.2T JPY
21%
17%
24%
32%
CH
Alcon AG
SIX:ALC
31.8B CHF
5%
3%
5%
4%
DK
Coloplast A/S
CSE:COLO B
126.6B DKK
21%
8%
19%
10%
US
Align Technology Inc
NASDAQ:ALGN
11.4B USD
10%
6%
15%
8%
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
46.5B CNY
20%
19%
21%
23%
UK
ConvaTec Group PLC
LSE:CTEC
4.6B GBP
13%
6%
11%
8%
CA
Bausch + Lomb Corp
NYSE:BLCO
5.9B USD
-5%
-2%
1%
1%
CH
Ypsomed Holding AG
SIX:YPSN
4.2B CHF
27%
16%
28%
18%
JP
Asahi Intecc Co Ltd
TSE:7747
823.8B JPY
8%
7%
18%
14%
US
Merit Medical Systems Inc
NASDAQ:MMSI
4.9B USD
8%
5%
7%
7%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less